UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2023



CARDLYTICS, INC. (Exact Name of Registrant as Specified in its Charter)

Delaware (State or other jurisdiction of incorporation or organization)

675 Ponce de Leon Avenue NE, Suite 6000

001-38386 (Commission File Number)

Atlanta Georgia (Address of principal executive offices, including zip code) (888) 798-5802 (Registrant's telephone, including area code) 26-3039436 (I.R.S. Employer Identification No.) 30308

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- □ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

<u>Title of each class</u> Common Stock

Trading symbol CDLX <u>Name of each exchange on which registered</u> The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On March 1, 2023, Cardlytics, Inc. (the "Company") issued a press release announcing its financial results for the quarter and year ended December 31, 2022, as well as information regarding a conference call to discuss these financial results and the Company's recent corporate highlights. The Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

ITEM 7.01 REGULATION FD DISCLOSURE.

On March 1, 2023, the Company is also posting a slide presentation on its website, which the Company will reference during the conference call described above. A copy of the slide presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.2 hereto shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Exhibit	Exhibit Description
99.1	Press release dated March 1, 2023
99.2	Presentation titled "Earnings Presentation Q4 2022"

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Cardlytics, Inc.

By:

March 1, 2023 Date:

/s/ Andrew Christiansen Andrew Christiansen Chief Financial Officer (Principal Financial and Accounting Officer) .



Cardlytics Announces Fourth Quarter and Fiscal Year 2022 Financial Results

Atlanta, GA – March 1, 2023 – Cardlytics, Inc., (NASDAQ: CDLX), a digital advertising platform, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022. Supplemental information is available on the Investor Relations section of the Cardlytics' website at http://ir.cardlytics.com/.

"We see a path to modest growth for 2023, especially after we lap the exit of a large customer from our channel in the second half of the year. We believe our numerous product initiatives that we are putting into place are setting us up for short and long-term success," said Karim Temsamani, CEO of Cardlytics. "We remain laser focused on driving product innovation and solutions for our partners and advertisers, and are excited about the expanded reach, revenue opportunities and efficiency this focus will create."

"Our fourth quarter performance was in line with our quarterly guidance ranges, and despite macro-related headwinds impacting consumer spending and ad budgets, we delivered double-digit year-over-year growth in 2022," said Andy Christiansen, CFO of Cardlytics. "We know our success is dependent on executing with a disciplined approach, and I am confident that our strategy and priorities are positioning the company for liquidity, long-term growth, and profitability."

Fourth Quarter 2022 Financial Results

- Total revenue was \$82.5 million, a decrease of (8.4)%, compared to \$90.0 million in the fourth quarter of 2021.
- Net loss attributable to common stockholders was \$(378.3) million, or \$(11.32) per diluted share, based on 33.4 million weighted-average common shares outstanding, compared to a net loss attributable to common stockholders of \$(11.8) million, or \$(0.35) per diluted share, based on 33.4 million weighted-average common shares outstanding in the fourth quarter of 2021.
 - Non-GAAP net loss was \$(9.7) million, or \$(0.29) per diluted share, based on 33.4 million weighted-average common shares outstanding in the fourth quarter of 2022, compared to a non-GAAP net loss of \$(5.0) million, or \$(0.15) per diluted share, based on 33.4 million weighted-average common shares outstanding in the fourth quarter of 2021.
- Billings, a non-GAAP metric, was \$126.1 million, a decrease of (5.9)%, compared to \$134.0 million in the fourth quarter of 2021.
- Adjusted contribution, a non-GAAP metric, was \$40.0 million, a decrease of (9.2)%, compared to \$44.0 million in the fourth guarter of 2021.
- Adjusted EBITDA, a non-GAAP metric, was \$(6.1) million, a decrease of \$8.7 million, compared to \$2.6 million in the fourth quarter of 2021.

Fiscal Year 2022 Financial Results

- Total revenue was \$298.5 million, an increase of 11.8%, compared to \$267.1 million in 2021.
- Net loss attributable to common stockholders was \$(465.3) million, or \$(13.92) per diluted share, based on 33.4 million weighted-average common shares outstanding, compared to a net loss attributable to common stockholders of \$(128.6) million, or \$(3.99) per diluted share, based on 32.2 million weighted-average common shares outstanding in 2021.
- Non-GAAP net loss was \$(57.4) million, or \$(1.72) per diluted share, based on 33.4 million weighted-average common shares outstanding in 2022, compared to a loss of \$(38.7) million, or \$(1.20) per diluted share, based on 32.2 million weighted-average common shares outstanding in 2021.
- Billings, a non-GAAP metric, was \$442.5 million, an increase of 12.3%, compared to \$394.1 million in 2021.
- Adjusted contribution, a non-GAAP metric, was \$143.0 million, an increase of 10.3%, compared to \$129.6 million in 2021.
- · Adjusted EBITDA, a non-GAAP metric, was a loss of \$(45.2) million, a decrease of \$(32.9) million, compared to a loss of \$(12.2) million in 2021.

Key Metrics

- Cardlytics MAUs in the quarter were 182.7 million, an increase of 4.2%, compared to 175.4 million in the fourth quarter of 2021. For full year 2022, Cardlytics MAUs were 186.7 million, an increase of 9.2%, compared to 170.9 million in 2021.
- Cardlytics ARPU in the quarter was \$0.45, a decrease of (7.8)%, compared to \$0.49 in the fourth quarter of 2021. For full year 2022, Cardlytics ARPU was \$1.55, an increase of 2.6%, compared to \$1.51 in 2021.
- Bridg ARR was \$23.1 million in the fourth quarter of 2022, an increase of 51.3% compared to \$15.3 million in the fourth quarter of 2021.
- Definitions of MAUs, ARPU and ARR are included below under the caption "Non-GAAP Measures and Other Performance Metrics."

First Quarter 2023 Financial Expectations

Cardlytics anticipates billings, revenue, and adjusted contribution to be in the following ranges (in millions):

	Q1 2023 Guidance
Billings ⁽¹⁾	\$84.0 - \$93.0
Revenue	\$54.0 - \$63.0
Adjusted contribution ⁽²⁾	\$26.0 - \$31.0
Adjusted EBITDA ⁽³⁾	(\$17.0) - (\$10.0)

- (1) A reconciliation of billings to GAAP revenue on a forward-looking basis is presented below under the heading "Reconciliation of Forecasted GAAP Revenue to Billings."
- (2) A reconciliation of adjusted contribution to GAAP gross profit on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.

(3) A reconciliation of adjusted EBITDA to GAAP net loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.

Earnings Teleconference Information

Cardlytics will discuss its fourth quarter and fiscal year 2022 financial results during a teleconference today, March 1, 2023, at 5:00 PM ET / 2:00 PM PT. A live dial-in will be available after registering at http://ir.cardlytics.com/. Shortly after the conclusion of the call, a replay of this conference call will be available through 8:00 PM ET on March 8, 2023 on the Cardlytics Investor Relations website at http://ir.cardlytics.com/. Following the completion of the call, a recorded replay of the webcast will be available on Cardlytics' website.

About Cardlytics

Cardlytics (NASDAQ: CDLX) is a digital advertising platform. We partner with financial institutions to run their rewards programs that promote customer loyalty and deepen relationships. In turn, we have a secure view into where and when consumers are spending their money. We use these insights to help marketers identify, reach, and influence likely buyers at scale, as well as measure the true sales impact of marketing campaigns. Headquartered in Atlanta, Cardlytics has offices in New York, Palo Alto, Austin, Los Angeles, Detroit, Champaign, and London. Learn more at www.cardlytics.com.

Cautionary Language Concerning Forward-Looking Statements:

This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, our financial guidance for the first quarter of 2023, our path to modest growth, the short- and long-term success of our product initiatives, our ability to achieve liquidity, long-term growth and profitability, the potential benefits of expanding our range of offerings and addressable markets and continuing progress across our strategic priorities. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "bould," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," intend," or variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control.

Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: risks related to unfavorable conditions in the global economy and the industries that we serve; our quarterly operating results have fluctuated and may continue to vary from period to period; our ability to sustain our revenue growth and bilings; risks related to our substantial dependence on our Cardlytics platform; risks related to our substantial dependence on JPMorgan Chase Bank, National Association ("Chase"), Bank of America, National Cascociation ("Bank of America"), Wells Fargo Bank, National Association ("Wells Fargo") and a limited to unuber of other financial institution ("FI") partners; risks related to our ability to maintain relationships with Chase, Wells Fargo and Bank of America; the amount and timing of budgets by marketers, which are affected by budget cycles, economic conditions and other factors, including the impact of the COVID-19 pandemic; our ability to generate sufficient revenue to offset contractual commitments to FIs; our ability to attract new partners, including FI partners, and maintain relationships with bank processors and digital banking providers; our ability to maintain relationships with marketers; our ability to adapt to change in consumer habits, negotiate fee arrangements with new and existing partners and retailers, and develop and launch new services and features; and other risks detailed in the "Risk Factors" section of our Form 10-K filed with the Securities and Exchange Commission. Past performance is not necessarily indicative of future results.

The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Non-GAAP Measures and Other Performance Metrics

To supplement the financial measures presented in our press release and related conference call or webcast in accordance with generally accepted accounting principles in the United States ("GAAP"), we also present the following non-GAAP measures of financial performance: billings, adjusted contribution, adjusted EBITDA, adjusted Partner Share and other third party costs, non-GAAP net loss and non-GAAP net loss per share as well as certain other performance metrics, such as monthly active users ("MAUs"), average revenue per user ("ARPU") and annualized recurring revenue ("ARR").

A "non-GAAP financial measure" refers to a numerical measure of our historical or future financial performance or financial position that is included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in our financial statements. We provide certain non-GAAP measures as additional information relating to our operating results as a complement to results provided in accordance with GAAP. The non-GAAP financial information presented herein should be considered in conjunction with, and not as a substitute for or superior to, the financial information presented in accordance with GAAP and should not be considered a measure of liquidity. There are significant limitations associated with the use of non-GAAP financial measures. Further, these measures may differ from the non-GAAP information, even where similarly titled, used by other companies and therefore should not be used to compare our performance to that of other companies. We have presented billings, adjusted contribution, adjusted EBITDA, adjusted Partner Share and other third party costs, non-GAAP net income (loss) and non-GAAP net income (loss) and non-GAAP retince (loss) and nor-GAAP financial measures in this press release. Billings represents the gross amount billed to customers and marketers for services in order to generate revenue. Cardlytics platform billings is recognized more show incremental revenue onur platform billings is recognized net of Consumer Incentives and gross of Partner Share. Bridg platform billings is the same as Bridg platform divent generate and other third-party costs exclusive of deferred implementation costs, which is a non-cash cost. Adjusted contribution does not take into account all costs associated with generating revenue from advertising campaigns, including sales and marketing expenses, research and development expenses, general and administrative expenses, net; depreciation and amortization expense; foreign currency gain (loss); impairment of goodwill and intargible

and reduction of force costs. We define non-GAAP net loss per share as non-GAAP net loss divided by our weighted-average common shares outstanding, diluted.

We believe the use of non-GAAP financial measures, as a supplement to GAAP measures, is useful to investors in that they eliminate items that are either not part of our core operations or do not require a cash outlay, such as stockbased compensation expense. Management uses these non-GAAP financial measures when evaluating operating performance and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures help indicate underlying trends in the business, are important in comparing current results with prior period results, and are useful to investors and financial analysts in assessing operating performance.

We define MAUs as targetable customers or accounts that have logged in and visited online or mobile applications containing offers from, opened an email containing offers from, or redeemed an offer from the Cardlytics platform during a monthly period. We then calculate a monthly average of these MAUs for the periods presented. We define ARPU as the total revenue generated in the applicable period calculated in accordance with GAAP, divided by the average number of MAUs in the applicable period. We define ARR as the annualized GAAP revenue of the final month in the period presented for the Bridg platform. ARR should not be considered in isolation from, or as an alternative to, revenue prepared in accordance with GAAP. We believe that ARR is an indicator of the Bridg platform's ability to generate future revenue from existing clients.

CARDLYTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in thousands)

	D	cember 31	l,
	2022		2021
Assets			
Current assets:			
Cash and cash equivalents	\$ 121,9	05 \$	233,467
Restricted cash		80	95
Accounts receivable and contract assets, net	115,6	09	111,085
Other receivables	4,4	70	6,097
Prepaid expenses and other assets	7,9	78	7,981
Total current assets	250,0	42	358,725
Long-term assets:			
Property and equipment, net	5,9	16	11,273
Right-of-use assets under operating leases, net	6,5	71	10,196
Intangible assets, net	53,4	75	125,550
Goodwill	352,7	21	742,516
Capitalized software development costs, net	19,5	25	13,131
Other long-term assets, net	2,5	86	2,406
Total assets	\$ 691,2	36 \$	1,263,797
Liabilities and stockholders' equity			
Current liabilities:			
Accounts payable	\$ 3.5	65 \$	4,619
Accrued liabilities:			
Accrued compensation	10,4	86	12,136
Accrued expenses	21,3		19,620
Partner Share liability	48.5	93	46,595
Consumer Incentive liability	53,9	83	52,602
Deferred revenue	1,7		3,280
Current operating lease liabilities	4.9	10	6,028
Current contingent consideration	104,1	21	182,470
Total current liabilities	248,9	44	327,350
Long-term liabilities:			
Convertible senior notes, net	226,0	47	184,398
Long-term deferred revenue		34	173
Long-term operating lease liabilities	4,3	06	6,801
Long-term contingent consideration		_	49,825
Other long-term liabilities		_	4,550
Total liabilities	479.6	31	573,097
Stockholders' equity:			
Common stock		9	9
Additional paid-in capital	1,182,5	68	1,212,823
Accumulated other comprehensive income	5.5		486
Accumulated deficit	(976,5		(522,618)
Total stockholders' equity	211,6		690,700
Total liabilities and stockholders' equity	\$ 691,2		1,263,797

CARDLYTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands except per share amounts)

	 ,				
	Three Months En	ded December 31,	Year Ended	Decem	ber 31,
	 2022	2021	2022		2021
Revenue	\$ 82,503	\$ 90,049	\$ 298,542	\$	267,116
Costs and expenses:					
Partner Share and other third-party costs	42,511	47,459	155,507		141,273
Delivery costs	6,583	6,427	30,403		22,503
Sales and marketing expense	16,825	18,998	74,745		65,996
Research and development expense	14,801	11,811	54,435		38,104
General and administration expense	20,065	17,085	81,446		66,222
Acquisition and integration costs (benefits)	1,395	1,446	(2,874)		24,372
Change in fair value of contingent consideration	(14,030)	(6,367)	(128,174)		1,374
Impairment of goodwill and intangible assets	370,139	-	453,288		_
Depreciation and amortization expense	 6,849	9,598	37,544		29,871
Total costs and expenses	 465,138	106,457	756,320		389,715
Operating loss	 (382,635)	(16,408)	(457,778)		(122,599)
Other (expense) income:					
Interest expense, net	(150)	(3,247)	(2,556)		(12,563)
Foreign currency gain (loss)	 4,506	(43)	(6,376)		(1,267)
Total other expense	4,356	(3,290)	(8,932)		(13,830)
Loss before income taxes	 (378,279)	(19,698)	(466,710)		(136,429)
Income tax benefit	_	7,864	1,446		7,864
Net loss	 (378,279)	(11,834)	(465,264)		(128,565)
Net loss attributable to common stockholders	\$ (378,279)	\$ (11,834)	\$ (465,264)	\$	(128,565)
Net loss per share attributable to common stockholders, basic and diluted	\$ (11.32)	\$ (0.35)	\$ (13.92)	\$	(3.99)
Weighted-average common shares outstanding, basic and diluted	 33,419	33,393	33,419		32,202

CARDLYTICS, INC. STOCK-BASED COMPENSATION EXPENSE (Amounts in thousands)

	Three Months En	ded I	December 31,	Year Ended	Decem	ber 31,
	 2022		2021	 2022		2021
Delivery costs	\$ 266	\$	482	\$ 2,682	\$	1,865
Sales and marketing expense	3,170		3,852	11,935		13,780
Research and development expense	3,843		3,197	13,262		10,328
General and administration expense	5,213		5,318	16,807		24,291
Total stock-based compensation expense	\$ 12,492	\$	12,849	\$ 44,686	\$	50,264

CARDLYTICS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands)

	Year Ended De	
	2022	2021
Operating activities		
Net loss	\$ (465,264) \$	\$ (128,56
Adjustments to reconcile net loss to net cash used in operating activities:		
Credit loss expense	2,399	1,70
Depreciation and amortization	37,544	29,87
Amortization of financing costs charged to interest expense	1,595	96
Accretion of debt discount and non-cash interest expense	-	9,51
Amortization of right-of-use assets	6,196	5,78
Impairment of goodwill and intangible assets	453,288	-
Stock-based compensation expense	44,686	50,26
Change in fair value of contingent consideration	(128,174)	1,37
Other non-cash expense, net	6,589	1,34
Deferred implementation costs	—	3,78
Income tax benefit	(1,446)	(7,86
Change in operating assets and liabilities:		
Accounts receivable	(4,546)	(27,93
Prepaid expenses and other assets	535	(1,46
Accounts payable	(893)	1,26
Other accrued expenses	(9,516)	(90
Partner Share liability	1,721	9,13
Customer Incentive liability	1,382	13,21
Net cash used in operating activities	(53,904)	(38,52
Investing activities		
Acquisition of property and equipment	(1,171)	(3,10
Acquisition of patents	(175)	(133
Capitalized software development costs	(12,140)	(9,32)
Business acquisitions, net of cash acquired	(2,274)	(494,13
Net cash used in investing activities	(15,760)	(506,69)
Financing activities		
Principal payments of debt	(35)	-
Proceeds from issuance of common stock	379	486,38
Deferred equity issuance costs	(157)	(19
Repurchase of common stock	(40,000)	
Debt issuance costs	(174)	(20
Net cash (used in) received from financing activities	(39,987)	485,99
Effect of exchange rates on cash, cash equivalents and restricted cash	(1.926)	(56
Net decrease in cash, cash equivalents and restricted cash	(111,577)	(59,78
Cash, cash equivalents, and restricted cash — Beginning of period	233,562	293,34
Cash, cash equivalents, and restricted cash — End of period	\$ 121,985	,

CARDLYTICS, INC. SUMMARY OF GAAP AND NON-GAAP RESULTS (Dollars in thousands)

	Three Months	5 Ende	d December 31,	Cha	nge		Year Ended	Decer	nber 31,		Chang	e
	2022		2021	 \$	%		2022		2021	_	\$	%
Billings ⁽¹⁾	\$ 126,11	.6 \$	133,973	\$ (7,857)	(6)%	\$	6 442,477	\$	394,075	\$	48,402	12 %
Consumer Incentives	43,61	.3	43,924	 (311)	(1)		143,935		126,959		16,976	13
Revenue	82,50	13	90,049	 (7,546)	(8)	_	298,542		267,116		31,426	12
Adjusted Partner Share and other third-party costs ⁽¹⁾	42,51	1	46,017	 (3,506)	(8)	_	155,507		137,488		18,019	13
Adjusted contribution ⁽¹⁾	39,99	2	44,032	 (4,040)	(9)	_	143,035		129,628		13,407	10
Delivery costs	6,58	3	6,427	156	2		30,403		22,503		7,900	35
Deferred implementation costs	-	-	1,442	 (1,442)	(100)		—		3,785		(3,785)	(100)
Gross profit	\$ 33,40	9 \$	36,163	\$ (2,754)	(8)%	\$	5 112,632	\$	103,340	\$	9,292	9 %
Net loss	\$ (378,27	9) \$	(11,834)	\$ (366,445)	n/a	\$	6 (465,264)	\$	(128,565)	\$	(336,699)	n/a
Adjusted EBITDA ⁽¹⁾	\$ (6,13	7) \$	2,560	\$ (8,697)	n/a	\$	6 (45,169)	\$	(12,220)	\$	(32,949)	n/a

(1) Billings, adjusted Partner Share and other third-party costs, adjusted contribution and adjusted EBITDA are non-GAAP measures. Reconciliations of these non-GAAP measures to the most comparable GAAP measures are presented below under the headings "Reconciliation of GAAP Net Loss to Adjusted EBITDA."

CARDLYTICS, INC. RECONCILIATION OF GAAP REVENUE TO BILLINGS (Amounts in thousands)

		Three Months Ended December 31, 2022			,	Three Months Ended December 31, 2021	
	Cardlytics Platform	Bridg Platform	Consolidated	Cardlytics Platform		Bridg Platform	Consolidated
Revenue	\$ 76,647	\$ 5,856	\$ 82,503	\$ 86,686	\$	3,363	\$ 90,049
Plus:							
Consumer Incentives	43,613	—	43,613	43,924		—	43,924
Billings	\$ 120,260	\$ 5,856	\$ 126,116	\$ 130,610	\$	3,363	\$ 133,973

		Year Ended December 31, 2022			Year Ended December 31, 2021						
	Cardlytics Platform	Bridg Platform	_	Consolidated		Cardlytics Platform	_	Bridg Platform		Consolidated	
Revenue	\$ 277,185	\$ 21,357	\$	298,542	\$	258,754	\$	8,362	\$	267,116	
Plus:											
Consumer Incentives	143,935	—		143,935		126,959		_		126,959	
Billings	\$ 421,120	\$ 21,357	\$	442,477	\$	385,713	\$	8,362	\$	394,075	

CARDLYTICS, INC. RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED CONTRIBUTION

(Amounts in thousands)		(Amounts	in	thousands)	
------------------------	--	----------	----	------------	--

			Three Months Ended December 31, 2022			Three Months Ended December 31, 2021	
	Cardly	tics Platform	Bridg Platform	Consolidated	 Cardlytics Platform	Bridg Platform	Consolidated
Revenue	\$	76,647	\$ 5,856	\$ 82,503	\$ 86,686	\$ 3,363	\$ 90,049
Minus:							
Partner Share and other third-party costs		42,375	136	42,511	47,274	185	47,459
Delivery costs ⁽¹⁾		5,271	1,312	6,583	4,618	1,809	6,427
Gross profit		29,001	4,408	 33,409	34,794	 1,369	 36,163
Plus:							
Delivery costs ⁽¹⁾		5,271	1,312	6,583	4,618	1,809	6,427
Deferred implementation costs ⁽²⁾		_	_	—	1,442	_	1,442
Adjusted contribution	\$	34,272	\$ 5,720	\$ 39,992	\$ 40,854	\$ 3,178	\$ 44,032

(1) Stock-based compensation expense recognized in consolidated delivery costs totaled \$0.3 million and \$0.5 million for the three months ended December 31, 2022 and 2021, respectively.

(2) Deferred implementation costs is excluded from adjusted Partner Share and other third-party costs as follows (in thousands):

				nree Months Ended December 31, 2022			Three Months Ended December 31, 2021	
	Cardlyt	ics Platform]	Bridg Platform	Consolidated	Cardlytics Platform	Bridg Platform	Consolidated
Partner Share and other third-party costs	\$	42,375	\$	136	\$ 42,511	\$ 47,274	\$ 185	\$ 47,459
Minus:								
Deferred implementation costs		_		_	_	1,442	_	1,442
Adjusted Partner Share and other third-party costs	\$	42,375	\$	136	\$ 42,511	\$ 45,832	\$ 185	\$ 46,017

CARDLYTICS, INC. RECONCILIATION OF GAAP GROSS PROFIT TO ADJUSTED CONTRIBUTION (Amounts in thousands)

	_	Year Ended December 31, 2022						Year Ended December 31, 2021						
	Card	Cardlytics Platform Bridg Platform			Consolidated			Cardlytics Platform		Bridg Platform		Consolidated		
Revenue	\$	277,185	\$	21,357	\$	298,542	\$	258,754	\$	8,362	\$	267,116		
Minus:														
Partner Share and other third-party costs		154,204		1,303		155,507		140,864		409		141,273		
Delivery costs ⁽¹⁾		24,112		6,291		30,403		18,111		4,392		22,503		
Gross profit		98,869		13,763		112,632		99,779		3,561		103,340		
Plus:														
Delivery costs ⁽¹⁾		24,112		6,291		30,403		18,111		4,392		22,503		
Deferred implementation costs ⁽²⁾		_		_		_		3,785		_		3,785		
Adjusted contribution	\$	122,981	\$	20,054	\$	143,035	\$	121,675	\$	7,953	\$	129,628		
					_									

(1) Stock-based compensation expense recognized in consolidated delivery costs totaled \$2.7 million and \$1.9 million for the years ended December 31, 2022 and 2021, respectively.

(2) Deferred implementation costs is excluded from adjusted Partner Share and other third-party costs as follows (in thousands):

			Year Ended December 31, 2022		Year Ended December 31, 2021						
	Cardl	ytics Platform		Bridg Platform		Consolidated	Cardlytics Platform		Bridg Platform		Consolidated
Partner Share and other third-party costs	\$	154,204	\$	1,303	\$	155,507	\$ 140,864	\$	409	\$	141,273
Minus:											
Deferred implementation costs		_		_		—	3,785		_		3,785
Adjusted Partner Share and other third-party costs	\$	154,204	\$	1,303	\$	155,507	\$ 137,079	\$	409	\$	137,488

CARDLYTICS, INC. RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA (Amounts in thousands)

	Three Months Ended December 31,				Ended 1ber 31,		
	 2022		2021	2022		2021	
Net loss	\$ (378,279)	\$	(11,834)	\$ (465,264)	\$	(128,565)	
Plus:							
Interest expense, net	150		3,247	2,556		12,563	
Depreciation and amortization	6,849		9,598	37,544		29,871	
Stock-based compensation expense	12,492		12,849	44,686		50,264	
Acquisition and integration costs (benefits)	1,395		1,446	(2,874)		24,372	
Change in fair value of contingent consideration	(14,030)		(6,367)	(128,174)		1,374	
Foreign currency (gain) loss	(4,506)		43	6,376		1,267	
Impairment of goodwill and intangible assets	370,139		_	453,288		_	
Restructuring and reduction of force	(347)		_	8,139		713	
Income tax benefit	_		(7,864)	(1,446)		(7,864)	
Deferred implementation costs	_		1,442	_		3,785	
Adjusted EBITDA	\$ (6,137)	\$	2,560	\$ (45,169)	\$	(12,220)	

CARDLYTICS, INC. RECONCILIATION OF ADJUSTED CONTRIBUTION TO ADJUSTED EBITDA (Amounts in thousands)

		Three Months Ended December 31, 2022						Three Months Ended December 31, 2021				
	Cardl	ytics Platform		Bridg Platform		Consolidated	_	Cardlytics Platform		Bridg Platform		Consolidated
Adjusted Contribution	\$	34,272	\$	5,720	\$	39,992	\$	40,854	\$	3,178	\$	44,032
Minus:												
Delivery costs		5,271		1,312		6,583		4,618		1,809		6,427
Sales and marketing expense		14,484		2,341		16,825		17,435		1,564		18,998
Research and development expense		13,002		1,799		14,801		10,531		1,280		11,811
General and administration expense		19,070		995		20,065		15,708		1,376		17,085
Stock-based compensation expense		(12,309)		(183)		(12,492)		(11,169)		(1,681)		(12,849)
Restructuring and reduction of force		347		_		347		_		_		_
Adjusted EBITDA	\$	(5,593)	\$	(544)	\$	(6,137)	\$	3,731	\$	(1,170)	\$	2,560

		Year Ended December 31, 2022		Year Ended December 31, 2021				
	Cardlytics Platform	Bridg Platform	Consolidated	Cardlytics Platform	Bridg Platform	Consolidated		
Adjusted Contribution	\$ 122,981	\$ 20,053	\$ 143,034	\$ 121,675	\$ 7,953	\$ 129,628		
Minus:								
Delivery costs	24,112	6,290	30,402	18,170	4,333	22,503		
Sales and marketing expense	67,830	6,915	74,745	62,771	3,225	65,996		
Research and development expense	47,579	6,856	54,435	35,393	2,711	38,104		
General and administration expense	79,069	2,377	81,446	63,379	2,843	66,222		
Stock-based compensation expense	(43,490)	(1,196)	(44,686)	(47,223)	(3,041)	(50,264)		
Restructuring and reduction of force	(8,139)	_	(8,139)	(713)	_	(713)		
Adjusted EBITDA	\$ (43,980)	\$ (1,189)	\$ (45,169)	\$ (10,102)	\$ (2,118)	\$ (12,220)		

CARDLYTICS, INC. RECONCILIATION OF GAAP NET LOSS TO NON-GAAP NET LOSS AND NON-GAAP NET LOSS PER SHARE (Amounts in thousands except per share amounts)

	Three Months Ended December 31,			Year Ended December 31,			
	 2022	2021	2022		2021		
Net loss	\$ (378,279)	\$ (11,834)	\$ (465,	264) \$	(128,565)		
Plus:							
Stock-based compensation expense	12,492	12,849	44,	686	50,264		
Foreign currency (gain) loss	(4,506)	43	6,	376	1,267		
Acquisition and integration costs (benefits)	1,395	1,446	(2,	374)	24,372		
Amortization of acquired intangibles	3,459	6,703	25,	019	19,712		
Change in fair value of contingent consideration	(14,030)	(6,367)	(128,	174)	1,374		
Impairment of goodwill and intangible assets	370,139	_	453,	288	_		
Restructuring and reduction of force	(347)	—	8,	139	713		
Income tax benefit	_	(7,864)	1,	446	(7,864)		
Non-GAAP net loss	\$ (9,677)	\$ (5,024)	\$ (57,	358) \$	(38,727)		
Weighted-average number of shares of common stock used in computing non-GAAP net loss per share:							
Non-GAAP weighted-average common shares outstanding, diluted	 33,419	33,393	33,	419	32,202		
Non-GAAP net loss per share attributable to common stockholders, diluted	\$ (0.29)	\$ (0.15)	\$ (1	.72) \$	(1.20)		

CARDLYTICS, INC. RECONCILIATION OF FORECASTED GAAP REVENUE TO BILLINGS (Amounts in millions)

Q1 2023 Guidance
\$54.0 - \$63.0
\$29.0 - \$31.0
\$84.0 - \$93.0

Contacts:

Investor Relations: Robert Robinson Corporate Development & IR ir@cardlytics.com

CARDLYTICS Q4 2022 Earnings Presentation

March 1, 2023

凾


Disclaimer

This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding expectations about future financial performance or results of Carolytics, Inc. ("Cardlytics," we, "is," or "our) including the potential benefits of our acquisitions of Doh, Bridg and Entertainment, becoming can how positive by the second half of 2023, earnings guidance for the first quarter of 2023, our part to modest growth, the short- and long-terms success of our product hiltitives, our entering voltance of proverhand profilability, fighting in constraints, and the provide statements are balaeted between events and terends discussed in this presentation may not occur and actual results could effer materially and adversity from these statements are balaeted between statements are under to identify forward-looking statements. The words "anticipate," believe, " continue," "estimate," "espect," "intend," "may," "will" and similar expressions are intended to identify forward-looking statements due to a number of fixes and uncertaintics, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially form those stateated or implied in forward-looking statements due to a number of fixes and uncertaintics, many of which involve factors or circumstances. The adversite of the out-state or and a balance or adversite state are beyond our control. Our actual results could differ materially form those stateated or implied in the forward-looking statements due to a number of fixes and builtings, fixes related to unfavorable conditions in the global economy and the industriss that we serve; our quarterly operating results have fluctuated and may continue to vary from period to period; our ability to sustain or adversitely from those stateated to use ability to sustain our constructure stateate adversite in the fixes related to countable conditions in the global economy and the industriss that we

In addition to U.S. GAAP financial information, this presentation includes billings, adjusted contribution, adjusted Partner Share and other third-party costs, adjusted EBITDA, adjusted EBITDA margin, non-GAAP net loss and non GAAP net loss per share, each of which is a non-GAAP financial measures are in addition to, and not a substitute for or superior to, measures of financial performance prepared in accordance with U.S. GAAP. Reconciliations of billings, adjusted CBITDA margin, adjusted Partner Share and other third-party costs, adjusted CBITDA, adjusted CBITDA margin, non-GAAP net loss and not a substitute for or superior to, measures of financial performance prepared in accordance with U.S. GAAP. Reconciliations of billings, adjusted CBITDA, adjusted CBITDA, adjusted CBITDA, adjusted CBITDA margin, non-GAAP net locs and not adjusted Partner Share and other third-party costs, adjusted EBITDA margin, non-GAAP net locs are included in the appendix to this presentation. Please see appendix for definitions.







Cardlytics provides a scaled solution based on purchase intelligence

Distinctive benefits for marketers

- + Reach valuable banking customers
- + Operate in a brand-safe, privacy-protected, trusted digital channel
- + Market to the most valuable customers based on their actual spending
- + Drive in-store and online traffic
- + Closed-loop solution measures marketing results to the penny

186M+

Monthly Active Users⁽¹⁾

\$4.1T+ in Annual Spend⁽²⁾

1 in 2 U.S. Purchase Transactions⁽³⁾

凾


5

Cardlytics is focused on five strategic initiatives to create shareholder value


Ad Server and Ads Manager adoption	 Connecting 100% of MAUs to new Ad Server by the end of 2023 Increasing adoption by agency, middle market and SMB clients
Next-gen customer experience	 Upgraded UI / UX for more content and better offer constructs, and engagement solutions to drive engagement and spend
Product & category offers	+ Delivering product-level offers across wider retail to provide advertisers enhanced flexibility and optionality
Grocery & CPG at scale	+ Scaled product-level offers from leading brands with a friction-free customer experience
Drive long-term growth & operating leverage	 Becoming cash flow positive by the second half of 2023 with continued self- funding of growth initiatives


凾

6



Trended consolidated results






凾

9

ー

Q4 2022 year-over-year consolidated results



4	113			(Amounts)	in thousands)
		Three Mo Decen	Change		
		2021	2022	\$	%
	Billings ⁽¹⁾	\$133,973	\$126,116	(\$7,857)	(5.9%)
	Consumer Incentives	43,924	43,613	(311)	(0.7%)
	Revenue	\$90,049	\$82,503	(\$7,546)	(8.4%)
	Adjusted Partner Share and other third-party $\mbox{costs}^{(1)}$	46,017	42,511	(3,506)	(7.6%)
	Adjusted contribution ⁽¹⁾	\$44,032	\$39,992	(\$4,040)	(9.2%)
	Delivery costs	6,427	6,583	156	2.4%
	Deferred implementation costs	1,442	-	(1,442)	(100.0%)
	Gross profit	\$36,163	\$33,409	(\$2,754)	(7.6%)
	Net (loss) income	(\$11,834)	(\$378,279)	(\$366,445)	n/a
	Adjusted EBITDA ⁽¹⁾	\$2,560	(\$6,137)	(\$8,697)	n/a

(1) Billings, adjuster andrer share and oner runs-party costs, adjuster combinition and a Resent results, encounted to all under the headings' Reconciliation of GAP Revenue to Billings', "Reconciliation of GAP Revenue to Billings', Bi

Cardlytics platform advertiser spend by industry

	% Change		% of Advertiser Spend							
TH	nree Months Endeo December 31,	d	Three Months Ended December 31,							
vs 2021	vs 2020	vs 2019	2019	2020	2021	2022				
> (10%)	> 50%	< 35 %	< 10%	> 10%	> 10%	> 5%				
> (40%)	> (35%)	> (35%)	< 30%	< 30%	< 25%	< 15%				
> (5%)	> 40%	< 35%	> 30%	> 30%	> 35%	> 35%				
> 75%	> 190%	> (10%)	> 15%	> 5%	> 5%	> 10%				
< (10%)	n/a	n/a	> 0%	> 0%	> 0%	< 5%				
> (5%)	> 20%	> 115%	< 15%	> 25%	> 25%	< 30%				
	vs 2021 > (10%) > (40%) > (5%) > 75% < (10%)	Three Months Ender December 31, vs 2021 vs 2020 > (10%) > 50% > (40%) > (35%) > (5%) > 40% > 75% > 190% < (10%)	Three Months Ended December 31, vs 2021 vs 2020 vs 2019 > (10%) > 50% < 35 %	Three Months Ended December 31, vs 2021 vs 2020 vs 2019 2019 >(10%) > 50% < 35 %	Three Months Ended December 31, Three Months December vs 2021 vs 2020 vs 2019 2019 2020 > (10%) > 50% < 35 %	Three Months Ended December 31, Three Months Ended December 31, vs 2021 vs 2020 vs 2019 2019 2020 2021 > (10%) > 50% < 35 %				

凾

Ð

Advertising spend from agency accounts grew > 20% during the fourth quarter of 2022 compared to the fourth quarter of 2021. Agency accounts represented > 10% of total advertising spend during the fourth quarter of 2022 compared to > 10% during the fourth quarter of 2021.

There may be variation in future quarters due to factors such as global economic events, bank launches, new advertisers with significant spend, and growth in nascent or new verticals.

Monthly log-in days⁽²⁾ show that MAUs logged in 10 days per month in Q4 2022 and Q4 2021.


Offer activation rates⁽²⁾ show higher rates for small-ticket, volume-heavy offers versus large-ticket and subscription offers.

Campaign spend ratios⁽²⁾ show Cardlytics currently targets a small proportion of total MAU spend.

- + As budgets increase and more advertisers come onto the platform, more spend from MAUs can be targeted with offers.
- + There remains considerable room to target larger audiences in light of existing MAU engagement levels.


Metrics include US users only
 Please see appendix for definitions

雨



13

Significant MAU increase precedes opportunity for expected billings growth and future ARPU expansion for the Cardlytics platform



14		
03		
US		
Appendix		
●		

Q4 2022 results

(Amounts	in thousands,	eveent	MALLE	and nor	share	amounts

	Three Mor Decem		Change		Year Ended December 31,		Change	
	2022	2021	AMT	%	2022	2021	AMT	%
Revenue	\$82,503	\$90,049	(\$7,546)	(8.4%)	\$298,542	\$267,116	\$31,426	11.89
Billings ⁽¹⁾	126,116	133,973	(7,857)	(5.9%)	442,477	394,075	48,402	12.39
Gross Profit	33,409	36,163	(2,754)	(7.6%)	112,632	103,340	9,292	9.0%
Adjusted contribution ⁽¹⁾	39,992	44,032	(4,040)	(9.2%)	143,035	129,628	13,407	10.39
Net income (loss) attributable to common stockholders	(378,279)	(11,834)	(366,445)	n/a	(465,264)	(128,565)	(336,699)	n/a
Net income (loss) per share (EPS), diluted	(\$11.32)	(\$0.35)	(\$10.97)	n/a	(\$13.92)	(\$3.99)	(\$9.93)	n/a
Adjusted EBITDA ⁽¹⁾	(\$6,137)	\$2,560	(\$8,697)	n/a	(\$45,169)	(\$12,220)	(\$32,949)	n/a
Adjusted EBITDA margin ⁽¹⁾⁽²⁾	(7.4%)	2.8%	10.2%	n/a	(15.1%)	(4.6%)	(10.6%)	n/a
Non-GAAP net loss ⁽¹⁾	(\$9,677)	(\$5,024)	(\$4,653)	n/a	(\$57,358)	(\$38,727)	(\$18,631)	48.1
Non-GAAP net loss per share ⁽¹⁾	(\$0.29)	(\$0.15)	(\$0.14)	n/a	(\$1.72)	(\$1.20)	(\$0.52)	43.3
Cardlytics MAUs (in millions)	186.7	175.4	11.3	6.4%	182.7	170.9	11.8	6.9%
Cardlytics ARPU	\$0.44	\$0.49	(\$0.05)	(10.2%)	\$1.55	\$1.51	\$0.04	2.65
Bridg ARR	\$23,129	\$15,282	\$7,847	51.3%	\$23,129	\$15,282	\$7,847	51.3
(1) Billings, adjusted contribution, adjusted EBITDA, non-GAAP net loss and non-GAA	P net loss per share are non-GAAP me	asures. Reconcilia	ations of these non-	GAAP measures	to the most compa	able GAAP measu	res are included in	the

 (1) Billings, adjusted contribution, adjusted EBITDA, non-GAAP net loss and non-GAAP net loss per share are appendix to this presentation, as well as definitions of these non-GAAP netrons.

 (2) Adjusted EBITDA margin is calculated as adjusted EBITDA divided by revenue.

Guidance

(Amounts in millions)

	Q1 2023 Guidance
Billings ⁽¹⁾	\$84.0 - \$93.0
Revenue	\$54.0 - \$63.0
Adjusted Contribution ^[1]	\$26.0 - \$31.0
Adjusted EBITDA ^{TI}	(\$17.0) - (\$10.0)

(1) Billings, adjusted contribution and adjusted EBITDA are non-GAAP measures. Definitions of these non-GAAP measures are included in the appendix to this presentation. A reconciliation of billings to GAAP revenue on a forward-looking basis is presented below under the heading "Reconciliation of Forecasted GAAP Revenue to Billings." A reconciliation of adjusted contribution to GAAP gross profit and a reconciliation of adjusted EBITDA to GAAP net loss on a forward-looking basis is not available without unreasonable efforts due to the high variability, complexity and low visibility with respect to the items excluded from this non-GAAP measure.

16

凾

Reconciliation of GAAP revenue to billings

	-											
		Three Months Ended										
	Mar 31, 2020	Jun 30, 2020	Sept 30, 2020	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021	Sept 30, 2021	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sept 30, 2022	Dec 31, 2022
Cardlytics Platform												
Revenue	\$45,509	\$28,222	\$46,079	\$67,082	\$53,230	\$56,763	\$62,075	\$86,686	\$63,983	\$69,270	\$67,285	\$76,647
Plus:												
Consumer Incentives	22,267	11,299	16,014	26,883	23,087	26,484	33,464	43,924	30,297	32,339	37,686	43,613
Billings	\$67,776	\$39,521	\$62,093	\$93,965	\$76,317	\$83,247	\$95,539	\$130,610	\$94,280	\$101,609	\$104,971	\$120,260
Bridg Platform												
Revenue		-		-		\$2,090	\$2,909	\$3,363	\$3,945	\$6,135	\$5,421	\$5,856
Plus:												
Consumer Incentives									-		-	-
Billings					· · ·	\$2,090	\$2,909	\$3,363	\$3,945	\$6,135	\$5,421	\$5,856
Consolidated												
Revenue	\$45,509	\$28,222	\$46,079	\$67,082	\$53,230	\$58,853	\$64,984	\$90,049	\$67,928	\$75,405	\$72,706	\$82,503
Plus:												
Consumer Incentives	22,267	11,299	16,014	26,883	23,087	26,484	33,464	43,924	30,297	32,339	37,686	43,613
Billings	\$67,776	\$39,521	\$62,093	\$93,965	\$76,317	\$85,337	\$98,448	\$133,973	\$98,225	\$107,744	\$110,392	\$126,116

18

凾

Reconciliation of GAAP gross profit to adjusted contribution

(Amounts in thousands)

		Three Months Ended											
Cardivtics Platform	Mar 31, 2020	Jun 30, 2020	Sept 30, 2020	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021	Sept 30, 2021	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sept 30, 2022	Dec 31, 2022	
Revenue	\$45,509	\$28,222	\$46,079	\$67.082	\$53,230	\$56,763	\$62,075	\$86,686	\$63,986	\$69,270	\$67,285	\$76,64	
Minus:	1.11		*		*******								
Partner Share and other third-party costs	26,138	16,811	27,971	38,388	29,771	29,890	33,929	47,274	35,027	39,403	37,399	42,375	
Delivery costs	3,405	3,499	3,498	3,907	3,938	4,837	4,777	4,618	4,907	6,311	7,623	5,271	
Gross Profit	\$15,965	\$7,912	\$14,610	\$24,787	\$19,521	\$22,036	\$23,369	\$34,794	\$24,049	\$23,556	\$22,263	\$29,00	
Plus:													
Delivery costs	3,406	3,499	3,498	3,907	3,938	4,837	4,777	4,618	4,907	6,311	7,623	5,271	
Deferred implementation costs	1,008	991	1,641	958	882	730	731	1,442					
Adjusted contribution	\$20,379	\$12,402	\$19,749	\$29,652	\$24,341	\$27,603	\$28,877	\$40,854	\$28,956	\$29,867	\$29,886	\$34,27	
Bridg Platform													
Revenue						\$2,090	\$2,909	\$3,363	\$3,945	\$6,135	\$5,421	\$5,856	
Minus:													
Partner Share and other third-party costs						63	161	185	126	877	164	136	
Delivery costs						911	1,613	1,809	1,626	1,851	1,502	1,312	
Gross Profit	+	а 1		-	-	\$1,116	\$1,135	\$1,369	\$2,193	\$3,407	\$3,755	\$4,408	
Plus:													
Delivery costs						911	1,613	1,809	1,626	1,851	1,502	1,312	
Adjusted contribution						\$2,027	\$2,748	\$3,178	\$3,819	\$5,258	\$5,257	\$5,720	
Consolidated													
Revenue	\$45,509	\$28,222	\$46,079	\$67,082	\$53,230	\$58.853	\$64.984	\$90.049	\$67,928	\$75,405	\$72,706	\$82,503	
Minus:													
Partner Share and other third-party costs	26,138	16,811	27,971	38,388	29,771	29,953	34,090	47,459	35,153	40,280	37,563	42,511	
Delivery costs	3,406	3,499	3,498	3,907	3,938	5,748	6,390	6,427	6,533	8,162	9,125	6,583	
Gross Profit	\$15,965	\$7,912	\$14,610	\$24,787	\$19,521	\$23,152	\$24,504	\$36,163	\$26,242	\$26,963	\$26,018	\$33,40	
Plus:													
Delivery costs	3,406	3,499	3,498	3,907	3,938	5,748	6,390	6,427	6,533	8,162	9,125	6,583	
Deferred implementation costs	1,008	991	1,641	958	882	730	731	1,442	-				
Adjusted contribution	\$20.379	\$12,402	\$19,749	\$29,652	\$24,341	\$29,630	\$31,625	\$44.032	\$32,775	\$35,125	\$35,143	\$39,99	

Reconciliation of GAAP partner share and other third-party costs to adjusted partner share and other third-party costs

	52					Three Me	onths Ended					
Cardlytics Platform	Mar 31, 2020	Jun 30, 2020	Sept 30, 2020	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021	Sept 30, 2021	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sept 30, 2022	Dec 31, 2022
Partner Share and other third-party costs	\$26,138	\$16,811	\$27,971	\$38,388	\$29,771	\$29,890	\$33,929	\$47,274	\$35,027	\$39,403	\$37,399	\$42,375
Minus:												
Deferred implementation costs	1,008	991	1,641	958	882	730	731	1,442				
Adjusted Partner Share and other third-party costs	\$25,130	\$15,820	\$26,330	\$37,430	\$28,889	\$29,160	\$33,198	\$45,832	\$35,027	\$39,403	\$37,399	\$42,375
iridg Platform												
artner Share and other third-party costs	2					\$63	\$161	\$185	\$126	\$877	\$164	\$136
/inus:												
Deferred implementation costs				-			-			-	÷	
Adjusted Partner Share and other third-party costs						\$63	\$161	\$185	\$126	\$877	\$164	\$136
onsolidated												
artner Share and other third-party costs	\$26,138	\$16,811	\$27,971	\$38,388	\$29,771	\$29,953	\$34,090	\$47,459	\$35,153	\$40,280	\$37,563	\$42,511
tinus:												
Deferred implementation costs	1,008	991	1,641	958	882	730	731	1,442		-		
Adjusted Partner Share and other third-party costs	\$25,130	\$15,820	\$26,330	\$37,430	\$28,889	\$29,223	\$33,359	\$46,017	\$35,153	\$40,280	\$37,563	\$42,511

(Amounts in thousands)

囤

Reconciliation of GAAP net (loss) income to adjusted EBITDA

		Three Months Ended										
	Mar 31, 2020	Jun 30, 2020	Sept 30, 2020	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021	Sept 30, 2021	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sept 30, 2022	Dec 31, 2022
Net (loss) income	(\$13,531)	(\$19,758)	(\$15,356)	(\$6,777)	(\$24,895)	(\$47,306)	(\$44,529)	(\$11,834)	\$33,038	(\$126,290)	\$6,267	(\$378,279)
Plus:												
Income tax benefit		-		-		-	-	(7,864)	-	(1,446)	-	-
Interest expense (income), net	(284)	10	283	3,039	3,045	3,078	3,193	3,247	947	879	580	150
Depreciation and amortization expense	2,331	1,545	1,933	2,017	3,065	8,833	8,375	9,598	9,871	10,356	10,468	6,849
Stock-based compensation expense	4,126	9,108	11,578	7,584	7,248	13,337	16,830	12,849	13,585	12,842	5,767	12,492
Foreign currency (gain) loss	1,886	8	(1,066)	(2,377)	(319)		1,543	43	1,671	4,538	4,673	(4,506)
Deferred implementation costs	1,008	991	1,641	958	882	730	731	1,442	5		5	100
Acquisition and integration costs (benefit)					7,030	14,182	1,714	1,445	(4,599)	2,197	(1,867)	1,395
Change in fair value of contingent consideration	4	ас.	9	2		1,480	6,261	(6,367)	(65,050)	(2,968)	(46,126)	(14,030)
Impairment of goodwill and intangible assets	-	-	2		-	-	-	-	÷	83,149	÷	370,139
Restructuring and reduction of force	482	403	391	47			713			958	7530	(347)
Adjusted EBITDA	(\$3,982)	(\$7,693)	(\$987)	\$4,444	(\$3,944)	(\$5,666)	(\$5,169)	\$2,560	(\$10,537)	(\$15,785)	(\$12,708)	(\$6,137)

ー

Reconciliation of adjusted contribution to adjusted EBITDA

		Three Months Ended											
ardivtics Platform	Mar 31, 2020	Jun 30, 2020	Sept 30, 2020	Dec 31, 2020	Mar 31, 2021	Jun 30, 2021	Sept 30, 2021	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sept 30, 2022	Dec 31 2022	
djusted Contribution	\$20,379	\$12,402	\$19,749	\$19,749	\$24,341	\$27,603	\$28,877	\$40,854	\$28,956	\$29,867	\$29,886	\$34,27	
linus:													
Delivery costs	3,406	3,499	3,498	3,498	3,938	4,837	4,777	4,618	4,907	6,311	7,623	5,275	
Sales and marketing expense	10,968	10,405	11,431	11,431	13,202	16,665	15,469	17,435	15,908	20,908	16,529	14,48	
Research and development expense	3,851	3,966	4,627	4,627	6,218	8,481	10,163	10,531	10,960	11,936	11,682	13,0	
General and administration expense	10,744	11,734	12,757	12,757	12,175	16,454	19,039	15,708	19,209	21,232	19,558	19,07	
Stock-based compensation expense	(4,126)	(9,108)	(11,578)	(11,578)	(7,248)	(13,179)	(15,627)	(11,169)	(11,935)	(13,944)	(5,302)	(12,30	
Restructuring and reduction of force	(482)	(403)	(391)	(391)			(713)			(958)	(7,530)	347	
Adjusted EBITDA	(\$3,982)	(\$7,691)	(\$595)	(\$595)	(\$3,944)	(\$5,656)	(\$4,231)	\$3,731	(\$10,093)	(\$15,618)	(\$12,674)	(\$5,5)	
ridg Platform													
Susted Contribution						\$2,027	\$2,748	\$3,178	\$3,819	\$5,258	\$5,257	\$5,7	
inus:													
Delivery costs						911	1,613	1,809	1,626	1,851	1,502	1,3	
Sales and marketing expense						398	1,264	1,564	1,740	1,075	1,760	2,3	
Research and development expense						453	978	1,280	1,331	1,645	2,080	1,7	
General and administration expense						434	1,034	1,376	1,216	(248)	414	. 99	
Stock-based compensation expense						(158)	(1,203)	(1,681)	(1,650)	1,102	(465)	[18	
Restructuring and reduction of force													
Adjusted EBITDA			-	· • · · · · · · · · · · · · · · · · · ·	5	(\$11)	(\$938)	(\$1,170)	(\$444)	(\$167)	(\$34)	(\$5	
onsolidated					-						_		
djusted Contribution	\$20,379	\$12,402	\$19,749	\$19,749	\$24,341	\$29,630	\$31,625	\$44,032	\$32,775	\$35,125	\$35,143	\$39,5	
linus:													
Delivery costs	3,406	3,499	3,498	3,498	3,938	5,748	6,390	6,427	6,533	8,162	9,125	6,58	
Sales and marketing expense	10,968	10,405	11,431	11,431	13,202	17,063	16,733	18,998	17,648	21,983	18,289	16,8	
Research and development expense	3,851	3,966	4,627	4,627	6,218	8,934	11,141	11,811	12,291	13,581	13,762	14,8	
General and administration expense	10,744	11,734	12,757	12,757	12,175	16,888	20,073	17,085	20,425	20,984	19,972	20,0	
Stock-based compensation expense	(4,126)	(9,108)	(11,578)	(11,578)	(7,248)	(13,337)	(16,830)	(12,849)	(13,585)	(12,842)	(5,767)	{12,4	
Restructuring and reduction of force	(482)	(403)	(391)	(391)			(713)			(958)	(7,530)	347	
Adjusted EBITDA	(53,982)	(\$7.691)	(\$595)	(\$595)	(\$3.944)	(\$5.666)	(\$5,169)	\$2,560	(\$10,537)	(\$15,785)	(\$12,708)	(\$6.1)	

(Amounts in thousands)

ー

Reconciliation of GAAP net loss to non-GAAP net loss and non-GAAP net loss per share

(Amounts in thousands, except							
		Three Months Ended December 31,		onths Ended aber 31,			
	2022	2021	2022	2021			
Vet loss	(\$378,279)	(\$11,834)	(\$465,264)	(\$128,565)			
Plus:							
Stock-based compensation expense	12,492	12,849	44,686	50,264			
Foreign currency (gain) loss	(4,506)	43	6,376	1,267			
Acquisition and integration costs (benefits)	1,395	1,446	(2,874)	24,372			
Amortization of acquired intangibles	3,459	6,703	25,019	19,712			
Change in fair value of contingent consideration	(14,030)	(6,367)	(128,174)	1,374			
Impairment of goodwill and intangible assets	370,139	5	453,288				
Restructuring and reduction of force	(347)		8,139	713			
Income tax benefit		(7,864)	1,446	(7,864)			
Non-GAAP net loss	(\$9,677)	(\$5,024)	(\$57,358)	(\$38,727)			
Veighted-average number of shares of common stock used in computing non-GAAP net loss per share:							
Weighted-average common shares outstanding, diluted	33,419	33,393	33,419	32,202			
Non-GAAP net loss per share attributable to common stockholders, diluted	(\$0.29)	(\$0.15)	(\$1.72)	(\$1.20)			

凾

23

凾

Reconciliation of forecasted GAAP revenue to billings

	(Amounts in millions)
	Q1 2023 Guidance
Revenue	\$54.0 - \$63.0
Plus:	
Consumer Incentives	\$29.0 - \$31.0
Billings	\$84.0-\$93.0

- 50

Adjusted contribution: We define adjusted contribution measures of the degree by which revenue generated from our marketers exceeds the cost to obtain the purchase data and the digital advertising space from our partners. Adjusted contribution demonstrates how incremental marketing ero our platform generates incremental amounts to support our vales and marketing, research and development, general and administration and other investments. Adjusted contribution is calculated by taking our total revenue less our Partner Share and other third-party costs exclusive of deferred implementation costs, which is a non-saft ocst. Adjusted contribution dees not take into account all costs associated with generating revenue from advertising campaigns, including sales and marketing expenses, research and development expenses, general and administrative expenses and other expenses, which we do not take into consideration when making decisions on how to manage our advertising campaigns.

Adjusted EBITDA: We define adjusted EBITDA as our (loss) income before income taxes; interest expense, net; depreciation and amortization expense; stock-based compensation expense; foreign currency gain (loss); deferred implementation costs; restructuring and reduction of force; acquisition and integration costs (benefit); Impairment of goodwill and intangible assets; and change in fair value of contingent considerations.

Bridg ARR: We define ARR as the annualized GAAP revenue of the final month in the period presented for the Bridg platform. ARR should not be considered in isolation from, or as an alternative to, revenue prepared in accordance with GAAP. We believe that ARR is an indicator of the Bridg platform's ability to generate future revenue from existing clients.

Cardlytics ARPU: We define ARPU as the total Cardlytics platform revenue generated in the applicable period calculated in accordance with GAAP, divided by the average number of MAUs in the applicable period.

Billings: Billings represents the gross amount billed to customers and marketers for advertising campaigns in order to generate revenue. Cardlytics platform billings is recognized gross of both Consumer Incentives and Partner Share. Cardlytics platform GAAP revenue is recognized net of Consumer Incentives and pross of Partner Share. Bridg platform billings is the same as Bridg platform GAAP revenue.

Campaign spend ratio: We define campaign spend ratio as the amount of spend from MAUs that is associated with the campaigns in which they were targeted with offers divided by the total amount of spend from MAUs in the industries in which MAUs were targeted with offers during the applicable period.

Cardlytics MAUs: We define MAUs as targetable customers or accounts that have logged in and visited online or mobile applications containing offers, opened an email containing an offer, or redeemed an offer from the Cardlytics platform during a monthly period. We then calculate a monthly average of these MAUs for the periods presented.

Monthly log-in days: We define monthly log-in days as the number of days in which MAUs logged in and visited the online or mobile banking applications of, or opened an email containing our offers from, our partners during a monthly period. We then calculate an average of the monthly log-in days for the periods presented.

Non-GAAP net loss: We define non-GAAP net loss as our net loss before stock-based compensation expense; foreign currency loss (gain); acquisition and integration costs (benefit); amortization of acquired intangibles; change in fair value of contingent considerations; Impairment of goodwill and intangible assets; and restructuring and reduction of force. Notably, any impacts related to minimum Partner Share commitments in connection with agreements with certain Partners are not added back to net loss in order to calculate adjusted EBITDA.

Non-GAAP net loss per share: We define non-GAAP net loss per share as non-GAAP net loss divided by GAAP weighted-average common shares outstanding, diluted.

Offer activation rate: We define offer activation rate as the total number of offers activated by MAUs divided by the total number of offers served to MAUs in the applicable period.

ー

Industry and account definitions

Segment	Segment Constituents
Agency	Merchants on the Cardlytics platform in which we interact with an advertising agency that we believe holds significant influence over the decision-making process as it relates to the design and management of advertising campaigns
Entertainment	Amusement Parks, Cinema/Video, Concerts/Theater, Gaming, Golf, Miscellaneous Recreation Services, Museums/Parks, Radio, Sporting & Sporting Venues/Other, Ticket Providers
Grocery & Gas	Convenience, Grocery
Other	Business Services, Financial Institutions, Gyms/Fitness, Home/ Maintenance, Online Education/ Distance Learning, Other Services, Salon/Spa
Restaurant	Banquet/Caterers, Bars/Night Clubs/Taverns, Fast Food/ Quick Serve, Full Service Restaurants, Quick Serve Light Fares
Retail	Accessories, Apparel, Auto Services and Products, Beauty Products/Cosmetics, Books/ Magazine, Child/ Infant Care, Drug Store/Pharmacy, General/Multi-Line, Home & Garden, Office Supplies, Other Retail, Pets, Shoes & Athletic Footwear, Specialty Gifts, Sporting & Outdoor Goods
Subscription	Bundled, Insurance/Real Estate, Internet, Phone, Professional Services, Television
Travel & Entertainment	Airlines, Car Rental, Cruise Lines, Gas Stations, Hotels/Lodging, Other Travel, Parking Services, Personal Transportation, Tour Operators/Agencies, Travel Aggregators and Agencies

ー

